3480 Peachtree Road NE
Second Floor, Suite 103
Atlanta, GA 30326
United States
844 722 6333
https://www.alzamend.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 4
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Stephan Jackman | CEO & Director | 434,24k | N/A | 1977 |
Mr. David J. Katzoff | Chief Financial Officer | 116,67k | N/A | 1963 |
Mr. Milton Charles Ault III | Founder & Vice Chairman | N/A | N/A | 1970 |
Mr. Henry C. W. Nisser Esq. | Executive VP, General Counsel & Director | 50k | N/A | 1969 |
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Alzamend Neuro, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.